Ascendis Pharma (NasdaqGS:ASND) FY Conference January 12, 2026 10:30 AM ET Company ParticipantsCharles Bruce - CardiologistSam Kulkarni - CEOScott Smith - CFODoug Ingram - CEONone - Unknown Speaker 1Jan Mikkelsen - CEONeil McCallum - CEONone - Unknown Speaker 2Diana Ramos - Surgeon General of CaliforniaConference Call ParticipantsBrian Cheng - Biotech AnalystAnupam Rama - Biotech AnalystModeratorGreat. Good morning. Welcome, everyone. I'm Jessica Fye, a biotech analyst at J.P. Morgan. We're so excited to be ...

Eli Lilly is reportedly looking to acquire French biotech Abivax, sending the latter company’s shares surging ahead of the J.P. Morgan Healthcare Conference 2026. According to a report by French news outlet La Lettre on 12 January, Eli Lilly is said to be working on a potential €15bn ($17.5bn) deal for Abivax, a company developing anti-inflammatory drugs. Eli Lilly declined to comment on business development activity, and Abivax did not immediately respond to Pharmaceutical Technology's request regardin ...

RENO, Nev. and SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ai Technology Group Inc. (OTCID:AIPG) (the “Company”) and AVM Biotechnology Inc. (“AVM”, the Washington State company that is the subject of the proposed merger) provide this joint press release. The Company continues with the funding of their proposed merger with AVM on an exclusive basis and announces we are in the process of extending funding dates to accommodate extended merger and financial audit timelines. The Company and AVM look forward to th ...

Group 1: Market Overview - Shares of Investor's Business Daily's Medical-Biomed/Biotech industry group surged in 2025, ending the year with a nearly 34% gain [4] - Futures for the Dow Jones Industrial Average and other major stock indexes traded sharply lower due to a criminal investigation into Federal Reserve Chairman Jerome Powell, with Dow Jones futures losing 0.7%, or around 350 points, in premarket trading [5] - Nasdaq underperformed as a tech rotation impacted Nvidia and other AI stocks, while Dow Jones futures rose before jobs data [10] Group 2: Company Highlights - Nvidia and Tesla were early losers in the stock market, indicating potential challenges for these companies [5] - Archer Aviation's stock jumped as it plans to outfit air taxis with Nvidia's AI technology [10] - Caterpillar is integrating AI and autonomy into construction sites, showcasing advancements in technology within the industry [10]

U.S. stock futures were lower this morning, with the Dow futures falling more than 300 points on Monday.Shares of Exelixis Inc (NASDAQ:EXEL) fell sharply in pre-market trading after the company announced preliminary fiscal year 2025 financial results.Exelixis reported preliminary 2025 US net product revenue of $2.123 billion. The company also said it sees 2026 net product revenue of $2.325 billion to $2.425 billion.Exelixis shares dipped 4.6% to $42.01 in pre-market trading.Here are some other stocks moving ...

Core Insights - The positive outlook on Nurix (NRIX) is driven by the innovative mechanism of action of the TPD modality and the significant difference in the duration of response observed in clinical studies [1] Group 1: Company Analysis - Nurix is positioned as a high-growth company within a sector expected to experience exponential expansion [1] - The focus is on understanding and investing in disruptive technologies and forward-thinking enterprises, indicating a strategic approach to innovation [1] Group 2: Investment Approach - The investment strategy combines fundamental analysis with future trend predictions, emphasizing the potential for substantial returns through innovation [1]

Full year MRD revenue growth of 46% driven by clonoSEQ® testing volumeSEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $7 ...

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) ("Zura†), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026. "We are excited to enter 2026, as we get closer to two potentially transformative readouts over the next 18 months for tibulizumab, starting with ant ...

U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower.Tensions flared up at the Federal Reserve after the Chair Jerome Powell said on Sunday that the Department of Justice had threatened the central bank with "criminal indictment" over his testimony before Congress, relating to its building renovation costs. This marks a major escalation in tensions between President Donald Trump and the central bank. On Friday, nonfarm payrolls increas ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) is included in our list of the stocks under $1 that will explode. Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances Oncolytics Biotech Inc. (NASDAQ:ONCY) shared a leadership update on January 7, 2026. With the appointment of Dr. Eileen O’Reilly of Memorial Sloan Kettering Cancer Center, Dr. Neil Segal of MSK, and Dr. Van Morris of MD Anderson Cancer Center, the company expanded its Gastrointestinal (GI) Tumor Scientific Advisory Board. The clini ...